higher prevalence and severity of the manifestations (6). The level of pigmentation 138 is then associated with the progression and severity of the disease(24).
139
Less specific, a diffuse corneal haze can also be found in conjunction with pigment symmetrical mirror image provided when pigments are second to drug deposits.
146
Clear understanding of the medical condition of the patient is obviously essential 147 to establish the differential diagnosis. in order to identify the source of the interactions.
334
For the categorical variables, the evolution of the initial time at 5 years was 335 categorized according to 3 categories (deterioration, stability and improvement).
336
The association between the evolution categories and the three groups was tested 337 using the exact p-value of the chi-square test.
338
All results were corrected for multiple comparisons.
339

RESULTS
340
The enrollment began in 2013, defined as baseline, and closed in February 2015.
341
The study ended in March 2017 after the fifth annual exam.
342
At baseline (2013) Statistical analysis will not consider the 2 products used differently.
363
The most common mutation affecting subjects (11/28) was p.Ala348Pro, a rare Table 2 . For statistical analysis, those single mutations will 366 be considered as a single group ("other mutations").
367
Age of the subjects are reported in high intra-subject variability between both eyes.
483
Once a MA was found in the bulbar conjunctiva, it was usually found also on the 
Cornea verticillata and haze
494
Corneal verticillata is certainly considered an important hallmark of ocular 495 manifestations related to Fabry. Corneal pigmentation was found in 10/10 Group 1 subjects at baseline, and at the end. Similar data was observed in Group 3 (9/10 497 at baseline and after 5 years). In Group 2, subjects slightly evolved in prevalence 498 from 5/8 to 6/8.
499
As reported in Table 6 modifications are graded from 0 (none) to 3 (severe), based on FOS scale(19).
546
Results can be found in Table 7 . There were differences among the groups. At 547 baseline, 9/10 subjects showed vessel tortuosity in Group 1, compared to 5/8 in
548
Group 2 and 4/10 in Group 3. The difference was found to be statistically significant 549 (F=3.781; p=0.0481 OD; F=4.634; p=0.0401 OS). More specifically, HTZ-ERT 550 subjects seemed to be more affected (prevalence) than HTZ-Non ERT subjects 551 (p=0.0438; 95%CI [-1.97, -0.41]). There was no significant evolution in prevalence 552 and severity of the condition over study time.
553
It is interesting to note that blood vessels silver wiring was noticed in 2 patients
554
(HMZ-advanced cases in severity), an occurrence that was not reported before.
DISCUSSION
556
This study tried to establish the prevalence and the natural course in intensity of 557 ocular manifestations, over 5 annual visits, in Fabry patients. Prevalence of the 558 ocular manifestations found in this study (see Table 8 
569
One important finding coming from the analysis of our data (Table 8) at the same population studied here, it was reported that switching from alphagal-579 beta to alfa form, both in standard dose, was associated with a transient increase
580
in clinical events for 6 months but thereafter the clinical event rate returned to 581 baseline for the next 3 years(77). Consequently, it is not likely that the switch of 582 enzyme had influenced the evolution of ocular manifestations observed here.
583
This study confirmed that cornea verticillata (photo 1) represents a proeminent 584 hallmark feature of Fabry disease, being present in almost every subject (89.2%). 
693
A second bias is the fact that all males recruited for the study were under treatment.
694
In a perfect world, a group of non-treated hemizygotes would had been followed 695 and compared to treated counterparts, as we were able to do for females. With 696 the same rationale, establishing a correlation between ocular manifestations 697 evolution and other outcomes i.e., kidney, heart, biomarkers that have been
698
reported to respond to ERTs would had been interesting. This study was not 699 designed for this purpose and limited access to the complete file of every patients,
700
for administrative and legal reasons, did not allow to proceed.
701
A third element to consider is the time of follow-up. For renal outcomes, the CFDI 702 reported a difference after 10 years but not after 5 years(41 
